Anavex Life Sciences Corp.
630 5th Avenue
New York
New York
10111
United States
Tel: 1-844-689-3939
Website: http://www.anavex.com/
Email: info@anavex.com
361 articles about Anavex Life Sciences Corp.
-
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
3/18/2024
Anavex Life Sciences Corp today announced that the first patient in its U.S. FDA cleared placebo-controlled Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia has been screened ahead of schedule.
-
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
2/26/2024
Anavex Life Sciences Corp. today announced that it will present at the 44th Annual TD Cowen Health Care Conference, March 4-6, 2024.
-
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
2/7/2024
Anavex Life Sciences Corp. today reported financial results for its fiscal quarter ended December 31, 2023.
-
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
2/1/2024
Anavex Life Sciences Corp. announced that it will issue financial results for its fiscal quarter ended December 31, 2023, on Wednesday, February 7, 2024.
-
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans
1/24/2024
Anavex Life Sciences Corp. today announced a peer-reviewed publication in Clinical Pharmacology in Drug Development, findings from the ANAVEX®3-71 first-in-human study which achieved its safety objectives.
-
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
1/16/2024
Anavex Life Sciences Corp. today announced the initiation of the U.S. FDA cleared placebo-controlled Phase 2 trial of ANAVEX®3-71 for the treatment of schizophrenia, which is expected to begin in Q2 2024. ANAVEX®3-71 positive initial Phase 1 results in healthy volunteers were previously reported.
-
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental DisordersGrant of Its Newest U.S. Patent Expands Anavex’s Intellectual Property Portfolio in Neurologic Indications
1/8/2024
Anavex Life Sciences Corp. announced it was granted new U.S. Patent No. 11,839,600 entitled “NEURODEVELOPMENTAL DISORDER THERAPY” from the United States Patent and Trademark Office for its patent application number 17/890,083.
-
Anavex Life Sciences' stock dropped by more than a third in value on Tuesday after results for a Phase II/III Rett syndrome study failed to impress investors.
-
Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference.
-
Anavex Life Sciences Provides an Update on Rett Syndrome Program
1/2/2024
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders reported topline results from the randomized, double-blind, placebo-controlled, Phase 2/3 EXCELLENCE clinical trial, which evaluated the clinical efficacy, safety, and tolerability of 30 mg ANAVEX®2-73 in 92 pediatric patients with Rett syndrome between the ages of 5 through 17 years.
-
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
12/20/2023
Anavex Life Sciences Corp. today announced the first entire clinical gene pathway data from the ANAVEX®2-73-RS-002 AVATAR Rett syndrome trial.
-
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
12/19/2023
Anavex Life Sciences Corp. announced today that the Committee for Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) agreed that oral blarcamesine for Alzheimer’s disease is eligible for submission of an application for a Union Marketing Authorisation in the EU under the European Medicines Agency’s centralised procedure.
-
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
11/27/2023
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today reported financial results for its fiscal year ended September 30, 2023.
-
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
11/24/2023
Anavex Life Sciences Corp. today announced that it will issue financial results for its fiscal year ended September 30, 2023, on Monday November 27, 2023.
-
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or AnxietyGrant of Its Newest U.S. Patent Expands Anavex’s Compounds Intellectual Property Portfolio
11/22/2023
Anavex Life Sciences Corp. today announced that the United States Patent and Trademark Office (USPTO) granted U.S. Patent No. 11,813,242 entitled “A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY, AND AGITATION”.
-
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)
11/20/2023
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders announced that representatives of Anavex met with team members of the European Medicines Agency.
-
Anavex Life Sciences Appoints Senior VP of Regulatory Affairs
11/6/2023
Anavex Life Sciences Corp. announced the appointment of David Goldberger, RPh, MLS as Senior Vice President Regulatory Affairs.
-
Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease
10/25/2023
Anavex Life Sciences Corp. today reported a new peer-reviewed publication in the journal Neurobiology of Aging, titled “Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology”, featuring the orally available small molecule ANAVEX®3-71 (AF710B).
-
Following a controversial Rett Syndrome trial last year, Anavex Life Sciences’ blarcamesine has claimed another clinical victory—this time in an Alzheimer’s disease Phase IIb/III study.
-
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows NeurodegenerationSignificant Reduction of Amyloid Beta Biomarkers of Alzheimer’s Pathology
9/14/2023
Anavex Life Sciences Corp. announced today that a follow-on analysis of the landmark Phase 2b/3 study to treat early Alzheimer’s disease with the investigational drug blarcamesine (ANAVEX ® 2-73) did demonstrate a statistically significant slowing in cognitive decline associated with Alzheimer’s disease.